Table 4:
Consensus question | Single-gene | Multigene |
---|---|---|
| ||
In general, should individuals with suspicion for a classic syndrome be considered for single gene or multigene panel testing? | 83% | 17% |
| ||
In general, should individuals without suspicion of a classic syndrome but at least one risk factor for hereditary kidney cancer be considered for single gene or multigene panel testing? | 10% | 90% |
| ||
Yes | No | |
| ||
An individual with kidney cancer undergoes somatic tumor profiling and is found with an alteration in a cancer gene associated with hereditary RCC (not VHL), in the absence of risk factors, should this individual undergo genetic risk assessment?* | 21% | 79%** |
| ||
If the above individual were to pursue genetic risk assessment for an alteration identified on a somatic panel, should testing consist of a single-gene assay? | 97% | 3% |
| ||
Should a negative somatic tumor profiling report (without germline testing) influence the decision to pursue genetic risk assessment? | 39% | 61% |
Statements in bold represent those with reached consensus
79% voted that the response to this question depends on the specific gene in question.